SG Americas Securities LLC Has $1.43 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

SG Americas Securities LLC lowered its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 79.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,582 shares of the medical instruments supplier's stock after selling 26,166 shares during the period. SG Americas Securities LLC's holdings in Insulet were worth $1,428,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Moneta Group Investment Advisors LLC raised its position in Insulet by 101,333.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier's stock worth $382,818,000 after buying an additional 1,299,095 shares during the last quarter. Geode Capital Management LLC raised its position in Insulet by 55.4% during the 1st quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier's stock worth $473,166,000 after buying an additional 529,926 shares during the last quarter. Clearbridge Investments LLC raised its position in Insulet by 38.8% during the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier's stock worth $452,016,000 after buying an additional 474,545 shares during the last quarter. William Blair Investment Management LLC raised its position in Insulet by 145.1% during the 3rd quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier's stock worth $116,894,000 after buying an additional 433,884 shares during the last quarter. Finally, Norges Bank purchased a new position in Insulet during the 4th quarter worth $105,275,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PODD shares. Morgan Stanley upgraded shares of Insulet from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $185.00 to $234.00 in a report on Monday, December 4th. Barclays cut their price target on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a report on Monday, February 26th. JPMorgan Chase & Co. increased their price target on shares of Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. Robert W. Baird upgraded shares of Insulet from a "neutral" rating to an "outperform" rating and increased their price target for the company from $180.00 to $238.00 in a report on Thursday, December 21st. Finally, Piper Sandler cut their price target on shares of Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $250.33.

Insulet Trading Up 1.3 %

PODD stock traded up $2.22 during midday trading on Friday, reaching $171.40. 786,601 shares of the company's stock traded hands, compared to its average volume of 865,549. The company has a market capitalization of $11.99 billion, a P/E ratio of 58.90, a PEG ratio of 3.09 and a beta of 0.98. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The business has a 50-day moving average price of $182.15 and a two-hundred day moving average price of $178.34.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million for the quarter, compared to analysts' expectations of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet's revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.55 earnings per share. Equities research analysts forecast that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares of the company's stock, valued at $418,215.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.90% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.